Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry
Our findings indicate that upadacitinib is effective and relatively safe for adolescents with moderate-to-severe AD; however, 33.3% discontinued treatment.
Authors
- Marijke Kamsteeg (ORCID: https://orcid.org/0000-0002-1389-2971)
- Marjolein S. de Bruin-Weller (ORCID: https://orcid.org/0000-0002-1249-6993)
- Paula P. van Lümig (ORCID: https://orcid.org/0000-0001-6619-0853)
- Laura Loman (ORCID: https://orcid.org/0000-0003-2731-9284)
- Lisa P. van der Rijst (ORCID: https://orcid.org/0000-0002-5865-8986)
- Florence Vroman (ORCID: https://orcid.org/0000-0002-9166-2864)
- Marlies de Graaf (ORCID: https://orcid.org/0000-0001-9004-5111)
- Nicolaas P. A. Zuithoff (ORCID: https://orcid.org/0000-0002-4441-1448)
- Marie L. A. Schuttelaar (ORCID: https://orcid.org/0000-0002-0766-4382)
- Octavian I. Bacoș‐Cosma (ORCID: https://orcid.org/0009-0006-2731-4562)
Institutions
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- University of Groningen (NL)
- Utrecht University (NL)
- Maastricht University Medical Centre (NL)
- University Medical Center (US)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
- Radboud Institute for Molecular Life Sciences (NL)
- Oklahoma State University Center for Health Sciences (US)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-07-30
- DOI
- https://doi.org/10.1080/09546634.2025.2539282
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- Almirall
- LEO Pharma
- Sanofi-Aventis Deutschland